血液感染檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、樣本類型、技術、最終用戶、地區和競爭對手分類，2021-2031年

全球血液感染檢測市場預計將從 2025 年的 8.505 億美元成長到 2031 年的 11.4041 億美元，複合年成長率達到 5.01%。

此領域涵蓋用於檢測和識別血液樣本中病原體（例如細菌和真菌）的診斷設備、耗材和軟體。其成長主要受敗血症發病率上升以及透過準確的病原學診斷控制抗生素抗藥性的重要性所驅動。歐洲疾病預防控制中心在2024年報告稱，歐盟第三代頭孢菌素抗藥性大腸桿菌血流感染的估計總發病率為每10萬人11.03例，凸顯了準確檢測在製定治療策略和促進患者康復方面發揮的關鍵作用，也強調了這一問題的緊迫性。

然而，自動化分子診斷系統的高成本和技術複雜性構成了市場推廣的重大障礙。許多醫療機構，尤其是在開發中國家，面臨預算限制，難以實施這些快速檢測方案，導致他們仍然依賴傳統的培養為基礎的檢測方法。這些經濟障礙阻礙了及時做出治療決策，限制了先進診斷技術的普及，並最終導致這些技術在最需要的地區無法應用。

市場促進因素

抗生素抗藥性的加劇是全球血液感染檢測市場的主要促進因素。隨著病原體發展出對抗標準療法的防禦機制，醫療機構對能夠同時識別致病菌並確定其抗生素敏感性譜的診斷工具的需求日益成長。抗藥性菌株的出現使得使用先進的檢測平台成為必要，以便進行精準的治療性介入並預防死亡。例如，英國衛生與安全局於2024年11月發布的《英格蘭抗生素處方和使用監測報告》指出，英格蘭由抗生素抗藥性引起的菌血症病例年增9.3%，2024年達到20484例。這凸顯了對能夠有效控制抗藥性感染疾病的診斷方法的迫切需求。

同時，快速分子診斷技術的進步顯著提高了病原體檢測的速度和準確性。傳統的培養方法需要數天才能得出結果，這可能導致敗血症治療的嚴重延誤，而現代平台可在數小時內提供可操作的數據，從而最佳化臨床工作流程。 T2 Biosystems公司於2024年3月在《臨床微生物學雜誌》（Journal of Clinical Microbiology）上發表的一項研究表明，T2抗藥性檢測板的靈敏度高達94.7%，且僅需4.4小時即可得出結果，而標準血液培養則需要超過58小時。這項功能優勢吸引了大量投資。根據《呼吸治療》（Respiratory Therapy）雜誌報道，診斷設備製造商Cytovale於2024年獲得了1億美元的D輪資金籌措，旨在加速將快速膿毒症檢測技術推廣到醫院系統。

市場挑戰

自動化分子診斷平台的高昂成本和技術複雜性是全球血液感染檢測市場擴張的主要障礙。高昂的實施成本以及對專業操作技能的要求，使得許多醫療機構，尤其是在財政狀況嚴峻的地區，難以採用這些系統。這些經濟和營運方面的障礙檢查室依賴耗時更長的傳統培養方法，導致關鍵治療決策延誤，並阻礙了現代檢測技術的應用。

由於診斷解決方案的預算撥款極少，醫療機構的購買力受到限制，這進一步加劇了其財務負擔。根據歐洲醫療技術協會（MedTech Europe）預測，至2024年，歐洲體外診斷支出僅佔醫療總支出的0.6%。此類投資限制凸顯了醫療機構在為部署高成本自動化平台資金籌措方面所面臨的挑戰。因此，持續的資金短缺直接阻礙了市場成長，因為全球大部分醫療機構仍然無法獲得這些設備的先進功能。

市場趨勢

人工智慧 (AI) 和機器學習演算法的整合正在從根本上改變臨床工作流程，將重點從簡單的病原體檢測轉移到預測性風險分層。與在感染確診後才識別病原體的傳統診斷方法不同，AI 模型分析宿主的免疫反應和生命徵象波動，從而提前數小時預測膿毒症的發生，使臨床醫生能夠在不可逆的器官損傷發生之前進行干預。為了支持這項創新，Prenosis 在 2024 年 4 月的新聞稿「Prenosis 的膿毒症新核准，該評分是一款用於膿毒症風險評估的 AI 工具」中宣布，其人工智慧工具已獲得首個上市核准，該工具可評估 22 個獨立參數。

策略性的產業重組和合作夥伴關係正在進一步加速市場變革，領先的診斷設備製造商致力於提供全面的端到端膿毒症管理解決方案。主要企業正在收購專注於特定領域的軟體和技術公司，以彌合診斷硬體與合理使用抗菌藥物管理之間的差距，將單一設備轉變為整合的數據生態系統，從而增強全院的決策能力。例如，生物梅里埃在2024年1月發布的新聞稿《生物梅里埃收購LUMED以加強軟體產品組合》中宣布，已完成約900萬歐元的投資，收購了這家軟體開發公司剩餘的股份，並將其臨床決策支援系統全面整合到其全球產品組合中。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球血液感染檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類別（試劑/耗材、設備）
  • 樣本類型（全血、血液培養）
  • 透過技術（PCR、質譜、原位雜合反應等）
  • 按最終用戶（醫院/診斷中心、客製化檢測服務供應商、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美血液感染檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲血液感染檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區血液感染檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲血液感染檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲血液感染檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球血液感染檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• bioMerieux SA
• Becton, Dickinson and Company
• Cepheid
• Seegene Inc
• T2 Biosystems, Inc
• F. Hoffmann-La Roche Ltd
• Siemens Healthcare Private Limited
• Luminex Corporation
• Bruker Corporation
• Accelerate Diagnostics, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Bloodstream Infection Testing Market is projected to expand from USD 850.50 Million in 2025 to USD 1140.41 Million by 2031, achieving a compound annual growth rate of 5.01%. This sector encompasses diagnostic instruments, consumables, and software utilized for the detection and identification of pathogens, such as bacteria and fungi, in blood samples. Growth is largely propelled by the rising incidence of sepsis and the critical necessity of managing antimicrobial resistance through accurate etiological diagnoses. Emphasizing this urgent need, the European Centre for Disease Prevention and Control reported in 2024 that the estimated total incidence of third-generation cephalosporin-resistant Escherichia coli bloodstream infections in the EU was 11.03 per 100,000 population, demonstrating the essential role of precise testing in directing therapeutic actions and enhancing patient recovery.

However, the market faces significant hurdles due to the high costs and technical complexities linked to automated molecular diagnostic systems. Numerous healthcare facilities, especially within developing nations, contend with budgetary limitations that preclude the acquisition of these rapid testing solutions, necessitating a continued reliance on slower, traditional culture-based methods. These financial barriers impede timely treatment decisions and restrict the global reach of advanced diagnostic technologies, thereby limiting their availability in regions where they are frequently most essential.

Market Driver

The escalating challenge of antimicrobial resistance serves as a primary driver for the Global Bloodstream Infection Testing Market. As pathogens develop defenses against standard treatments, healthcare providers are increasingly seeking diagnostic tools capable of both identifying causative agents and determining antibiotic susceptibility profiles. This rise in resistant strains mandates the use of advanced testing platforms to facilitate precise therapeutic interventions and prevent fatalities. For instance, the UK Health Security Agency's November 2024 'English surveillance of antibiotic prescribing and utilisation report' highlighted that bacteraemia cases attributed to antibiotic resistance in England rose by 9.3% year-over-year, totaling 20,484 cases in 2024, underscoring the demand for diagnostics that manage resistant infections effectively.

Concurrently, breakthroughs in rapid molecular diagnostic technologies are transforming the speed and precision of pathogen detection. While traditional culture methods can take days to produce results-a potentially fatal delay in sepsis management-modern platforms offer actionable data within hours to optimize clinical workflows. A study published in the 'Journal of Clinical Microbiology' in March 2024 involving T2 Biosystems demonstrated that the T2Resistance Panel achieved 94.7% sensitivity and provided results in only 4.4 hours, compared to more than 58 hours for standard blood cultures. This functional advantage is attracting significant investment; according to Respiratory Therapy, diagnostic firm Cytovale secured $100 million in Series D funding in 2024 to accelerate the deployment of its rapid sepsis testing technology across hospital systems.

Market Challenge

The substantial expense and technical intricacy associated with automated molecular diagnostic platforms present a major obstacle to the expansion of the Global Bloodstream Infection Testing Market. High acquisition prices combined with the need for specialized operational skills make these systems unattainable for many healthcare facilities, particularly in areas facing strict financial constraints. These economic and operational barriers compel laboratories to rely on slower, traditional culture methods, which delays critical treatment decisions and hinders the widespread adoption of modern testing technologies.

This financial strain is further highlighted by the minimal budget allocation for diagnostic solutions, which restricts the purchasing capacity of medical institutions. According to MedTech Europe, expenditure on in vitro diagnostics accounted for merely 0.6% of total healthcare spending in Europe in 2024. Such restricted investment underscores the challenges facilities face in funding high-cost automated platforms. Consequently, market growth is directly impeded as the advanced capabilities of these instruments remain inaccessible to a significant portion of the global healthcare sector due to enduring funding limitations.

Market Trends

The integration of Artificial Intelligence and Machine Learning algorithms is fundamentally transforming clinical workflows by shifting focus from simple pathogen detection to predictive risk stratification. Unlike conventional diagnostics that identify organisms after an infection is established, AI models analyze host-immune responses and vital sign fluctuations to predict sepsis onset hours in advance, allowing clinicians to intervene before irreversible organ damage occurs. Validating this innovation, Prenosis announced in an April 2024 press release titled 'Prenosis Announces FDA De Novo Marketing Authorization of the Sepsis ImmunoScore' that it received the first-ever marketing authorization for an AI tool assessing 22 distinct parameters to evaluate patient sepsis risk.

Strategic industry consolidations and collaborative partnerships are further driving market evolution as major diagnostic players aim to provide comprehensive, end-to-end sepsis management solutions. Leading companies are acquiring niche software and technology firms to bridge the gap between diagnostic hardware and antimicrobial stewardship, converting standalone instruments into integrated data ecosystems that enhance hospital-wide decision-making. Illustrating this approach, bioMerieux announced in a January 2024 press release titled 'bioMerieux acquires LUMED to reinforce its software portfolio' that it completed an investment of nearly 9 million euros to acquire the remaining capital of the software developer, thereby fully integrating its clinical decision support systems into their global offering.

Key Market Players

• bioMerieux SA
• Becton, Dickinson and Company
• Cepheid
• Seegene Inc
• T2 Biosystems, Inc
• F. Hoffmann-La Roche Ltd
• Siemens Healthcare Private Limited
• Luminex Corporation
• Bruker Corporation
• Accelerate Diagnostics, Inc

Report Scope

In this report, the Global Bloodstream Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bloodstream Infection Testing Market, By Product

• Reagents & Consumables
• Instruments

Bloodstream Infection Testing Market, By Sample Type

• Whole Blood
• Blood Culture

Bloodstream Infection Testing Market, By Technology

• PCR
• Mass Spectroscopy
• In Situ Hybridization
• Others

Bloodstream Infection Testing Market, By End User

• Hospitals & Diagnostic Centers
• Custom Laboratory Service Providers
• Academic & Research Institutes
• Others

Bloodstream Infection Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bloodstream Infection Testing Market.

Available Customizations:

Global Bloodstream Infection Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bloodstream Infection Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Reagents & Consumables, Instruments)
  • 5.2.2. By Sample Type (Whole Blood, Blood Culture)
  • 5.2.3. By Technology (PCR, Mass Spectroscopy, In Situ Hybridization, Others)
  • 5.2.4. By End User (Hospitals & Diagnostic Centers, Custom Laboratory Service Providers, Academic & Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Bloodstream Infection Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Sample Type
  • 6.2.3. By Technology
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bloodstream Infection Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Sample Type
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Bloodstream Infection Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Sample Type
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Bloodstream Infection Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Sample Type
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By End User

7. Europe Bloodstream Infection Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Sample Type
  • 7.2.3. By Technology
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bloodstream Infection Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Sample Type
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By End User
  • 7.3.2. France Bloodstream Infection Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Sample Type
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Bloodstream Infection Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Sample Type
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Bloodstream Infection Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Sample Type
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Bloodstream Infection Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Sample Type
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By End User

8. Asia Pacific Bloodstream Infection Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Sample Type
  • 8.2.3. By Technology
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bloodstream Infection Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Sample Type
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By End User
  • 8.3.2. India Bloodstream Infection Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Sample Type
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Bloodstream Infection Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Sample Type
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Bloodstream Infection Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Sample Type
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Bloodstream Infection Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Sample Type
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By End User

9. Middle East & Africa Bloodstream Infection Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Sample Type
  • 9.2.3. By Technology
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bloodstream Infection Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Sample Type
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Bloodstream Infection Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Sample Type
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Bloodstream Infection Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Sample Type
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By End User

10. South America Bloodstream Infection Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Sample Type
  • 10.2.3. By Technology
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bloodstream Infection Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Sample Type
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Bloodstream Infection Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Sample Type
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Bloodstream Infection Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Sample Type
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bloodstream Infection Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. bioMerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Becton, Dickinson and Company
• 15.3. Cepheid
• 15.4. Seegene Inc
• 15.5. T2 Biosystems, Inc
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Siemens Healthcare Private Limited
• 15.8. Luminex Corporation
• 15.9. Bruker Corporation
• 15.10. Accelerate Diagnostics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer